[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:acute-lymphoblastic-leukemia:ms4a1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Acute Lymphoblastic Leukemia","MS4A1 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06918431","Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:15:53.461103Z","2026-04-29T02:57:57.072943Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:24.494016Z","2026-07-05T05:32:16.752213Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[27],"Phase 1","2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z"]